Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice

Antimicrob Agents Chemother. 2002 Jan;46(1):132-4. doi: 10.1128/AAC.46.1.132-134.2002.

Abstract

Ceftriaxone is highly effective clinically in patients with Lyme disease. We studied a representative invasive human isolate of Borrelia burgdorferi for which the MBC of ceftriaxone was 0.050 microg/ml. A once-per-day dosage regimen of ceftriaxone (50 mg/kg/dose) administered intramuscularly for 5 days was 100% effective in sterilizing tissue samples of C3H mice infected with this strain of B. burgdorferi, regardless of whether the mice were being treated concomitantly with a corticosteroid. Administration of the same five doses of ceftriaxone at 6-h intervals over just 24 h was also 100% effective. These experiments suggest that shorter courses of antibiotics than those currently recommended should be considered for study in patients with early uncomplicated Lyme disease.

MeSH terms

  • Animals
  • Borrelia burgdorferi / drug effects
  • Ceftriaxone / blood
  • Ceftriaxone / therapeutic use*
  • Cephalosporins / therapeutic use*
  • Disease Models, Animal
  • Female
  • Lyme Disease / blood
  • Lyme Disease / drug therapy*
  • Mice
  • Mice, Inbred C3H
  • Treatment Outcome

Substances

  • Cephalosporins
  • Ceftriaxone